Quantcast

Latest Idebenone Stories

2014-09-10 12:28:50

However, Less Than One-Third of Duchenne Patients Are in Subpopulations That Will Benefit From New Disease-Modifying Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the first three emerging disease-modifying therapies (DMTs)--PTC Therapeutics' Translarna (ataluren), Prosensa's drisapersen and Sarepta's eteplirsen--will likely receive regulatory approval for Duchenne muscular dystrophy (DMD) in...

2011-07-26 12:07:50

A clinical trial led by Newcastle University shows that the drug, idebenone (Catena®), improved the vision and perception of colour in patients with Leber's Hereditary Optic Neuropathy (LHON). The inherited condition means patients, who can see normally, lose the sight in one eye then within 3 to 6 months lose the sight in their other eye. In some severely affected patients such as those who were unable to read any letters on the chart, the treatment with idebenone resulted...

2011-07-26 07:07:17

(Ivanhoe Newswire) -- A clinical trial led by Newcastle University shows that the drug, idebenone improved the vision and perception of color in patients with Leber's Hereditary Optic Neuropathy (LHON). The inherited condition means patients, who can see normally, lose the sight in one eye then within 3 to 6 months lose the sight in their other eye. In some severely affected patients such as those who were unable to read any letters on the chart, the treatment with idebenone resulted in a...

2008-10-10 09:00:18

LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada. The drug is indicated for the treatment of Friedreich's Ataxia, a rare neuromuscular disease that results in the degeneration of nerve and muscle tissue. Catena is the first and only approved therapy in Canada to treat this devastating genetic disorder. Santhera...

2008-07-24 12:01:22

Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena. Launch of Catena is anticipated by the end of October 2008. In clinical studies submitted to Health Canada as part of the approval process,...

2008-07-24 03:00:18

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia. Health Canada's decision is the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena(R). Santhera has established a wholly owned Canadian subsidiary,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related